Cellectis raises $228.3M, lists in U.S.

Immunotherapy company Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) lost $2.20 to $39.30 in its first day of trading on NASDAQ on Wednesday after raising

Read the full 224 word article

How to gain access

Continue reading with a
two-week free trial.